These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 23494872)

  • 21. Estimation in flexible two stage designs.
    Brannath W; König F; Bauer P
    Stat Med; 2006 Oct; 25(19):3366-81. PubMed ID: 16220489
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exact statistical inference for group sequential trials.
    Lin DY; Wei LJ; DeMets DL
    Biometrics; 1991 Dec; 47(4):1399-408. PubMed ID: 1786325
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mixed noninferiority margin and statistical tests in active controlled trials.
    Tsou HH; Hsiao CF; Chow SC; Yue L; Xu Y; Lee S
    J Biopharm Stat; 2007; 17(2):339-57. PubMed ID: 17365228
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adaptive extensions of a two-stage group sequential procedure for testing primary and secondary endpoints (II): sample size re-estimation.
    Tamhane AC; Wu Y; Mehta CR
    Stat Med; 2012 Aug; 31(19):2041-54. PubMed ID: 22733687
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An adaptive confirmatory trial with interim treatment selection: practical experiences and unbalanced randomization.
    Heritier S; Lô SN; Morgan CC
    Stat Med; 2011 Jun; 30(13):1541-54. PubMed ID: 21432887
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparison of confidence interval methods for the intraclass correlation coefficient in cluster randomized trials.
    Ukoumunne OC
    Stat Med; 2002 Dec; 21(24):3757-74. PubMed ID: 12483765
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Issues with statistical risks for testing methods in noninferiority trial without a placebo ARM.
    Hung HM; Wang SJ; O'Neill R
    J Biopharm Stat; 2007; 17(2):201-13. PubMed ID: 17365218
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Conditional and unconditional confidence intervals following a group sequential test.
    Fan X; DeMets DL
    J Biopharm Stat; 2006; 16(1):107-22. PubMed ID: 16440840
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Blinded sample size re-estimation in three-arm trials with 'gold standard' design.
    Mütze T; Friede T
    Stat Med; 2017 Oct; 36(23):3636-3653. PubMed ID: 28608469
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Statistical inference on censored data for targeted clinical trials under enrichment design.
    Chen CF; Lin JR; Liu JP
    Pharm Stat; 2013; 12(3):165-73. PubMed ID: 23606647
    [TBL] [Abstract][Full Text] [Related]  

  • 31. On the lower predictive bound approach for noninferiority clinical trials with binary data.
    Liu Q; Li Y
    J Biopharm Stat; 2014; 24(6):1225-38. PubMed ID: 25036815
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Issues of simultaneous tests for noninferiority and superiority.
    Ng TH
    J Biopharm Stat; 2003 Nov; 13(4):629-39; discussion 641-62. PubMed ID: 14584713
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An efficient and exact approach for detecting trends with binary endpoints.
    Shan G; Ma C; Hutson AD; Wilding GE
    Stat Med; 2012 Jan; 31(2):155-64. PubMed ID: 22162106
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of the statistical power for multiple tests: a case study.
    Yeo A; Qu Y
    Pharm Stat; 2009; 8(1):5-11. PubMed ID: 18381588
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Group sequential t-test for clinical trials with small sample sizes across stages.
    Shao J; Feng H
    Contemp Clin Trials; 2007 Sep; 28(5):563-71. PubMed ID: 17434814
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An adaptive design to bridge the gap between Phase 2b/3 microbicide effectiveness trials and evidence required for licensure.
    Taylor DJ; Grobler A; Abdool Karim SS
    Clin Trials; 2012 Aug; 9(4):377-84. PubMed ID: 22610168
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Power analyses for correlations from clustered study designs.
    Tu XM; Kowalski J; Crits-Christoph P; Gallop R
    Stat Med; 2006 Aug; 25(15):2587-606. PubMed ID: 16025545
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Type I error and power in noninferiority/equivalence trials with correlated multiple endpoints: an example from vaccine development trials.
    Kong L; Kohberger RC; Koch GG
    J Biopharm Stat; 2004 Nov; 14(4):893-907. PubMed ID: 15587971
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Confidence interval estimation of the intraclass correlation coefficient for binary outcome data.
    Zou G; Donner A
    Biometrics; 2004 Sep; 60(3):807-11. PubMed ID: 15339305
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlation coefficient inference on censored bioassay data.
    Li L; Wang WW; Chan IS
    J Biopharm Stat; 2005; 15(3):501-12. PubMed ID: 15920894
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.